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ABSTRACT 
Clinical studies of dopamine cell replacement therapies for Parkinson’s disease (PD) go back more than 
30 years. The outcomes using transplantation of human fetal ventral mesencephalic tissue (hfVM) 
have been variable, with some patients coming off their anti-PD treatment for many years, while other 
patients have not responded and/or developed significant side effects, including graft-induced 
dyskinesias. This led to a re-appraisal of how trials should best be done which resulted in a new EU 
funded allograft trial with fetal dopamine cells across several centres in Europe. This new trial, 
TRANSEURO1 (NCT01898390); is an open label study in which patients were randomly selected for 
transplantation out of a larger observational cohort of patients with mild PD undergoing identical 
assessments. The TRANSEURO trial is currently ongoing, having completed both recruitment into a 
large multicentre observational study of younger onset early stage PD as well as transplantation of 
hfVM in 11 patients. While completion of TRANSEURO is not expected until 2021, we feel that sharing 
the rationale for the design of TRANSEURO, along with lessons we have learned along the way, can 
help to inform researchers and facilitate planning of human pluripotent stem cell-derived dopamine 
cell transplants for future clinical trials. 
 
Introduction 
Parkinson’s disease (PD) is a chronic neurodegenerative disorder that is characterised by the loss of 
nigrostriatal dopaminergic neurons and the development of a movement disorder typically in the 7th 
to 8th decade of life. Pathologically the disease is defined by the accumulation of alpha synuclein in 
Lewy bodies and Lewy neurites which extends across many areas of the central nervous system (CNS) 
as well as involving the enteric and autonomic nervous systems 2. This widespread pathology explains 
many of the non-motor abnormalities patients which PD experience, only some of which are 
responsive to dopaminergic medications 3. Nevertheless, the core motor deficits of bradykinesia and 
rigidity are responsive to dopaminergic replacement therapies, and patients typically do very well 
when treated with such drugs in the early stages of disease. However, oral dopaminergic drugs cause 
both short and long-term problems. These include off target effects leading to neuropsychiatric and 
autonomic problems as well as dyskinesias through the non-physiological stimulation of dopaminergic 
receptors in the striatum. As a result, there has long been an interest in using different approaches to 
target selectively the loss of dopamine at the site of greatest depletion, namely the putamen, including 
gene and cell based therapies 4,5. These therapies have now both been trialled in patients with mixed 
benefits. 
In 2006, a new international initiative was conceived followed by a series of meetings to re-evaluate 
the merit of dopamine cell-based therapies for PD. This was deemed necessary given the contrasting 
outcomes of the two NIH funded human fetal ventral mesencephalic (hfVM) allograft trials in PD that 
were published in 2001 and 2003 6,7compared to earlier open-label studies using similar tissue 
(reviewed in 8). These NIH funded double-blind placebo-controlled studies reported no benefits in 
grafted versus sham-operated patients and, in addition, significant numbers of patients developed 
side effects in the form of graft-induced dyskinesias (GIDs). These results were at odds with earlier 
open-label studies reporting long-term benefits, which led to the need to explore how such disparate 
results could be reconciled.  
The meetings invited all the main investigators involved in these trials and sought to critically appraise 
the previous work, with the aim of deciding whether this therapeutic approach had a future and if so, 
how best to move it forward for PD. Based on these discussions and an analysis of the raw data 
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collated from all major hfVM trials in PD, the group identified factors that were thought to explain 
some of the differences in patients who had a positive outcome following this intervention. In 
particular, it appeared that disease stage at time of grafting was critical. This in turn led to the 
hypothesis, that patients at an earlier disease stage with no significant ventral striatal dopaminergic 
denervation and negligible dyskinesias may benefit the most from hfVM grafts as well as being less 
likely to develop GIDs.  
Based on this reasoning, a new EU funded transplant trial in Europe using hfVM tissue, called 
TRANSEURO was initiated (NCT01898390). This tissue was chosen for implantation in 2010 (when the 
trial began) as there were no published protocols for making authentic and functional human stem 
cell derived midbrain dopaminergic neurons. This TRANSEURO multicentre study had two major arms; 
(i) an observational study charting the natural history of younger onset, early stage PD (N>100) (the 
group thought to be optimal for dopamine cell therapies); and (ii) a transplant arm involving patients 
randomly selected from this observational cohort (provided they had continued adherence to 
eligibility criteria)1.  
The observational study is still ongoing with a significant proportion of the cohort being followed up 
to the present day. The transplant arm has now been completed with 11 patients grafted over a 3 year 
period (2015-2018). The outcome of these hfVM transplants will be evaluated in 2021 using the 
predefined primary end point of the trial, which will be the Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) part 3 score in the defined “OFF” state. We will also 
compare the transplant group against the trajectory of patients in the well-matched 
contemporaneously studied control group of the TRANSEURO study.  
In this Perspective we describe both the observational and the transplant arms of the TRANSEURO 
trial in terms of how they were designed as well as some of the data from the observational cohort 
justifying our approach. We also discuss some of the major issues that arose during this work which 
are likely to be important and relevant in the new stem cell-based therapies that are soon to enter 
clinical trials for PD. We think that there is a need to present such information at this stage, since the 
primary end-point in the TRANSEURO transplant trial will be reported at a time when several stem 
cell-derived dopamine transplant clinical trials for PD will have already started9. 
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The TRANSEURO study ( 
FIGURE 1 HERE 
Observational study 
The recruitment of patients with idiopathic PD started in December 2010 and continued until the end 
of 2013 at several sites- Addenbrooke’s Hospital, Cambridge, UK; Imperial College, London, UK; 
National Hospital for Neurology and Neurosurgery, London, UK; University of Cardiff, UK; Skåne 
University Hospital, Lund, Sweden; Freiburg University, Germany and at the Assistance Publique-
Hôpitaux de Paris (APHP), France. Inclusion and Exclusion criteria are detailed in Text Box 1.  
TEXT BOX 1 HERE 
After recruitment, patients were seen every 6 months in the “OFF” medication state and a detailed 
number of assessments were undertaken (see Figure 1 for details) that were selected to objectively 
capture motor, cognitive, psychiatric, and other non-motor symptoms as well as quality of life 
measures. These were chosen to ensure that: (i) the most widely recognised clinical assessments were 
included for ease of cross study comparisons; (ii) all included measures were validated and (iii) all 
measures could be completed in a timely manner and were acceptable to participants. 
Given the practical difficulties associated with observer bias, all motor assessments were video-taped 
while participants wore caps to hide any clues regarding surgery. This allows for blinding regarding 
treatment allocation among independent raters who will score the videos at a later date.  
Finally, despite randomisation, surgical trials involving small numbers of patients can be vulnerable to 
outlying data from individuals with conspicuously fast or slow rates of disease progression/ atypical 
responses to interventions, some of which have a genetic basis. To try and partially mitigate against 
this, all participants are currently being genotyped for the common known PD genes, some of which 
have been documented to play a role on rate of disease progression10.  
Throughout the study, the patients’ medication was managed according to best medical practice and 
no changes or alterations were made explicitly for the execution of this trial, but only as clinically 
indicated by the treating physician. Patients enrolled to the observational study were informed that 
they may be selected for the transplant study but this was not guaranteed. They were also informed 
that if they were not included in the transplant part of this study that they may still be suitable down 
the line for other experimental cell and gene-based dopamine therapies for their PD as well as for 
DBS. 
Transplant study 
The inclusion and exclusion criteria for transitioning into the transplant arm of TRANSEURO were 
reapplied to a subset of patients who were selected at random to either 1) form the transplant arm 
of the trial or 2) to act as a matched control population in terms of clinical assessments and PET 
imaging. Some additional measures were added (see Text Box 1 and Figure 1). These criteria were 
carefully chosen to ensure patients participating in the trial were likely to be at the lowest risk from 
the transplantation procedure and yet have the highest chance of clinical benefit, while remaining 
representative of the main population of PD patients in the early stages of the disease.  Given the 
longitudinal nature of the project, and concerns regarding issues such as GIDs, it was essential during 
the patient selection process for transplantation that the criteria at baseline were reapplied at the 
time of grafting to avoid recruiting patients who had developed significant L-dopa induced dyskinesias 
(LIDs) during the observational follow up period. This period of observational follow up was extremely 
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valuable in allowing for the assessment of the rate of progression of motor severity of early PD using 
the MDS-UPDRS part 3 in both the OFF and ON drug conditions. The MDS-UPDRS part 3 is a well 
validated standard clinical assessment tool used to measure motor function in PD and was the reason 
we adopted it in TRANSEURO. Moreover, the re-application of criteria ahead of transplantation 
allowed for an increasing confidence of the accuracy of the diagnosis of PD by introducing a threshold 
of a documented 33% response to L-dopa between ON vs OFF assessments. 
Finally, the assessment of patients in the transplant arm of TRANSEURO was identical to that 
undertaken in the observational arm. The primary outcome chosen is the change in MDS-UPDRS part 
3 motor score after a defined period of medication withdrawal (Practically defined OFF) at 36 months 
after their final transplant, comparing these patients with those not grafted (see Text Box 2). The 
longitudinal “observational’’ data obtained prior to transplant has allowed this measure to be selected 
as the primary outcome with confidence, with the additional advantage that any change in MDS-
UPDRS part 3 trajectory could be assessed according to treatment allocation. 
TEXT BOX 2 HERE 
Imaging studies done as part of this study 
Anatomical imaging using MRI was undertaken in the selected transplant cohort ahead of grafting to 
plan their implantation surgery. MRI scanning was also routinely done in the immediate post-
operative period to assess for (i) graft placement; (ii) any complications such as haemorrhages or other 
abnormalities. 
In addition, MRI and PET imaging studies were undertaken to look at functional aspects of the 
transplant, in particular its ability to normalise network activity as well as dopaminergic content and 
dopamine transporter (DAT) expression and dopamine transporter (DAT) expression as assessed with 
18F-dopa and 11C-PE2I respectively as well as contamination by 5HT neurons (using 11C-DASB PET 
imaging) given the possible role of serotonin in the genesis of GIDs 11(see Figure 1). In addition, we 
used 18F -dopa PET imaging as an inclusion/exclusion criterion for the transplant arm (see Text Box 1), 
given that it has previously been reported that significant preoperative ventral striatal dopamine loss 
is associated with less successful outcomes in patients receiving hfVM transplants 12.  
The functional and structural imaging studies using MRI was done to ascertain whether the 
transplant could restore cortical networks back to a more normal state 13. This included resting state 
network activity, (RSNs- fMRI), motor task activation (ME fMRI) and diffusion tensor imaging (DTI). 
This PET and MRI imaging battery was repeated every 18 months in the grafted patients. 
One additional criterion for transplantation was introduced for pragmatic reasons to accommodate 
the imaging protocols, that of dominant handedness. Given the impact that dominant handedness has 
on functional imaging using fMRI, the decision was taken to only perform transplantation on right 
hand dominant individuals. While this restriction was not desirable from the clinical perspective, the 
compromise was taken in light of the considered importance of the imaging data. 
Human fetal VM tissue (hfVM) preparation for transplantation 
The preparation of the hfVM tissue for grafting in patients in the TRANSEURO trial was modified such 
that a more defined set of standard operating procedures (SOPs) compared to the previous trials were 
followed. Tissue dissection and preparation was undertaken in either a GMP facility (in the UK) or a 
clean room (in Sweden). The SOPs were validated extensively in a series of preclinical in vitro and in 
vivo studies including animal models of PD 14,15, to ensure that the tissue could consistently and 
reproducibly be dissected to yield the number of dopamine cells thought to be needed to repair the 
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putamen in the PD brain (>100,000 cells per side grafted). We also, for the first time, in a clinical trial 
used hfVM tissue that had been collected from medical as well as surgical terminations of pregnancy, 
based on pre-clinical validation showing that tissue collected via either route was equivalent in terms 
of dopaminergic cell yields following transplantation16 (unpublished data).  
Given the source of the cells in the TRANSEURO trial, all donors and recipients had HIV, HBV, HCV, 
HTLV-1, HSV, chlamydia and syphilis testing to ensure that no viral or spirochaete transmission 
occurred and that there were no additional risks for disease reactivation in the host through 
immunosuppression in the post-operative period. Furthermore, donor tissue and recipients had to 
have CMV, EBV and toxoplasma serology – to ensure optimal donor matching around possible 
infective risk. 
An absolute requirement to be fulfilled for transplantation was that we had tissue from at least 3 hfVM 
specimens per side grafted, aged between 6-8 weeks post conception. This was based on previous 
data from open label trials indicating that around 100,000 surviving DA neurons in the grafted 
putamen were needed for major clinical improvement, and that a minimum of 3 hfVMs are needed to 
reach this number17,18. The tissue was also stored for no more than 4 days after dissection in Hibernate 
E and lazaroids19 and the viability of the cell preparation on the day of surgery had to be >80%. These 
requirements meant that over the 3 year course of the transplant trial, many scheduled surgeries were 
cancelled because of insufficient amounts of tissue and on one occasion because of poor tissue 
viability (see Table 1).This emphasises the need to have a more readily available source of cells for 
grafting that does not rely on the unpredictable harvesting of fresh human fetal tissue. Indeed, 
consideration was given for abandoning the transplant trial given the major logistical problems we 
encountered. While this was not done, a decision was made that we would continue to graft patients 
until either all 20 selected cases had been transplanted bilaterally or a 3 year period from the time of 
the first transplant had elapsed. The latter was reached first and thus only 11 patients were grafted in 
the transplant arm of the TRANSEURO study.  
The transplantation procedure 
The transplantation approach targeting the putamen was deduced using data from previous trials and 
the level of innervation seen around individual deposits of hfVM18. Thus, we adopted an established 
surgical implantation that had shown good post mortem evidence of coverage of the putamen with 
the grafted dopamine cells in terms of innervation.  
Two unilateral stereotactic procedures per patient were undertaken under general anaesthesia with 
5 tracts per hemisphere: 2 into the pre-commissural and 3 into the post-commissural putamen. Eight 
deposits per tract were made with 2.5ul of cell suspension placed at each deposit along the needle 
tract commencing at the bottom of the target. A total volume 100 ul of cell suspension was grafted 
per procedure. The tissue was delivered using a modified version of the Rehncrona instrument 
developed for the original Lund transplant studies of the 1980s/1990s. The interval between the two 
surgeries varied from 4 to 35 weeks. 
Broad spectrum antibiotics were administered at the time of surgery to prevent introduction of 
infection. 
The immunosuppressive regime adopted  
Immunosuppressive therapy was given for 12 months post transplantation and comprised a standard 
triple therapy (see below). This was in line with what had been used in previous allograft trials of hfVM 
tissue in PD, in particular the Lund program in the 1980s/1990s.  
7 
 
The immunosuppression was started the day before the 1st graft and consisted of: Ciclosporin, 2mg/kg 
twice a day (giving serum levels between 100-200ng/ml); Azathioprine, 2mg/kg per day; Prednisolone, 
40mg per day, reducing to 5mg by 12 weeks. To cover possible side effects, the following agents were 
also given daily; Omeprazole and Calcichew; Co-trimoxazole 3x a week and Alendronic acid once a 
week. 
The follow up, timing of primary end points and choice of comparator in the transplant trial 
Transplantation of immature dopaminergic neuroblasts brings with it a need for long-term follow up 
to monitor efficacy and possible delayed side effects. In the case of hfVM grafts, maximum benefit is 
probably not seen for several years- possibly as much as 3-5 years20. A primary end-point that is 
sufficiently far from the time of grafting is therefore needed. We decided to have a 3 year primary end 
point in TRANSEURO, which also reduces the likelihood of any placebo effects related to the surgery.  
As to what is the optimal primary end point is debatable, but given that we are trialling a dopamine 
cell therapy-it makes sense to use an end point that is known to be very sensitive to this aspect of the 
pathology in PD21. As such, we elected to use the MDS-UPDRS part 3 motor score in the defined OFF 
period – while also collecting a large number of secondary end points (see Text Box 2).  
In addition to the trial steering committee we set up an independent Data Safety Monitoring 
Committee that was involved in the transplant study and asked to comment on adverse events and 
whether the trial should be stopped or suspended based on such events or could continue. 
Data analysis of the observational data 
The clinical outcomes were analysed for trends over time using multilevel models, allowing each 
patient to have their own rate of decline (varying intercept and varying slope model). The main 
parameter of interest is the average rate of change across all patients, and only a linear effect of time 
was included.  The models were fitted with  Bayesian statistical software22 and the brms R package23 . 
The output of these models is the estimated annual rate of change and a 95% confidence interval (CI). 
P-values (see Figure 2) indicate the probability that the effect is in the opposite direction (that is, 
patients improve over time). For each outcome, the time at which the 95% CI excludes the baseline 
value is calculated and represents when a change from baseline can be detected, providing an 
estimate of an outcome’s sensitivity to detect changes. We also assessed whether age and disease 
duration (at baseline) could predict the rate of decline of UPDRS Part III, using a simple linear 
regression, but incorporating the uncertainty in the estimated rate of change values (Figure 2). 
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Lessons learnt from the TRANSEURO study and its implications for future cell based trials in PD 
Observational study 
The number of patients originally recruited to each site is given in Figure 1, and the numbers at each 
follow-up visit are also recorded and the reasons for drop-out are given. These data reveal a number 
of issues that will inform studies moving forward. Firstly, recruiting patients at this stage and age with 
PD is not problematic, but retaining them in studies is harder when the assessment protocols are long. 
This is compounded by the need for them to be assessed OFF treatment and the fact that there is no 
guarantee that they will be randomised into the treatment arm of the study. Furthermore, recruiting 
patients across multiple international sites generated its own problems in terms of: (a) differences in 
national regulation of observational studies and its application to the trial; (b) oversight of 
assessments and staff; (c) stability of that centre as a research site. All of these are major issues when 
setting up long-term studies of this type, taking many years to complete. In TRANSEURO, at one of the 
centres, the PI resigned and his team dissipated and thus we lost the ability to follow up the entire 
patient cohort from this site.  
We did find that the cohort we chose to study were well suited for trials of this type, as we had 
predicted, and there were no major problems recruiting such patients. In particular, we found (see 
Figure 2): 
o Patients progressed in a linear fashion over a 3 year period with respect to their scores on the 
MDS-UPDRS part 3 in the defined OFF state. This should therefore allow for disease 
modifications/deviations to be easily seen with any intervention over this time frame 
including dopamine cell transplants. In particular, we found the total UPDRS motor score 
significantly increased by 3.9 points a year (95% CI = 3.0-4.8) with a change from baseline 
being detected at 7 months, demonstrating that the measure is sensitive to temporal disease 
progression. 
o Figure 2 shows the estimated monthly rate of change in the UPDRS-III (motor) score by age; 
error bars are standard errors, and the uncertainty in the rate of change is propagated into 
this analysis. Older patients deteriorated at a faster rate than younger patients, with the 
average 65 year-old deteriorating at nearly twice the rate as the average 40 year-old (p = 
0.023). However, the considerable patient-to-patient variability means that the chance of a 
randomly selected 65 year-old deteriorating at a faster rate than a randomly selected 40 year-
old is only 70%. There was little evidence of an association between disease duration and 
clinical outcomes. 
o Patients did NOT develop any major cognitive problems over this time, as we anticipated given 
the inclusion/exclusion criteria we adopted for patient recruitment. In particular, the total 
score for the Revised Addenbrooke's Cognitive Examination (ACE-R) remained stable over the 
entire 36 month period and was well outside the cognitively impaired range. 
o Patients did not develop significant dyskinesias as assessed by the Abnormal Involuntary 
Movement Scale (AIMS). In fact, LIDs were seen in very few patients and then with minimal 
impact and only at the end of the 3 year observational period. 
Implications: 
We would recommend using this nested trial approach for first in-human stem cell derived dopamine 
cell studies as it has many merits in terms of a well-matched natural history control for comparison 
against intervention, as well as allowing for patients to act as their own controls. However, the extent 
of testing should be carefully considered as to what key information is actually needed in such trials 
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and how much of this needs to be collected in the OFF-medication state. This is especially problematic 
for the participants and was the cause of several of them dropping out from the trial (see Figure 1). 
The reason for looking at the “OFF” medication condition relates to the major fluctuation in motor 
features that occurs in some individuals even in early disease as a result of L-dopa replacement. One 
solution to this would have been to restrict recruitment to patients free from dopaminergic 
replacement. However, this would have placed a major restriction on the longitudinal aspects of the 
trial, as well as creating ethical concerns when it came to the transplant part of the study. 
In retrospect, restricting the recruitment and follow-up of patients to 1-2 sites makes logistical and 
regulatory sense given some of the issues that we found in the setting up and execution of our 
observational study, which included issues with sponsorship and trial classification (Clinical Trial of an 
Investigational Medicinal Product (CTIMP) versus non-CTIMP). 
Finally the patient selection criteria and assessment tools we have developed in TRANSEURO would 
seem to be a useful platform to build upon when moving forward. Whether there are additional 
measures that could be used, should be further explored- especially around wearable devices, which 
currently hold great promise for monitoring disease progression. However, there are no major 
limitations with the assessments we have used to date in that they have enabled us to select what we 
think may be the optimal group for this type of intervention.  
Transplant study 
Eleven patients were randomly selected for transplantation out of 150 patients recruited to the 
observational study. Originally, the number to be grafted was 20 patients, but because of major issues 
of tissue supply (see above), the number was reduced. This issue of tissue supply was the single biggest 
problem we encountered in this trial. 
The principle of selecting patients from a cohort that is already recruited and being followed up long 
term, and then applying the same assessment protocol to the grafted patients seems logical in early 
stage trials as it: (i) helps to ensure there are good pre-intervention clinical data defining the disease 
trajectory for individual patients (i.e., they act as their own controls); (ii) increases the likelihood that 
the diagnosis of PD is correct, given that misdiagnosis becomes evident as patients evolve and their 
response to dopaminergic medication becomes clearer; (iii) guarantees a good contemporaneous 
comparator cohort by which to assess the intervention without the need for sham surgery early on in 
trials, which will be an issue in the first in human stem cell clinical trials for PD; and (iv) ensures that 
any practice effects with tests have plateaued by the time of intervention. 
Implications: 
It is clear that trials with hfVM tissue are not viable going forward given the problems of tissue supply 
(see above). Thus, stem cell derived cells are essential if this field is to progress. We also believe that 
recruiting suitable individuals from an observational cohort of patients, that have been followed up 
for at least 12-24 months prior to any planned intervention would be ideal. Finally patients should be 
tested on an assessment protocol that can be used not only to follow disease course but can also serve 
to detect a signal of graft efficacy and ideally should involve scoring from video recordings of patients 
wearing caps to minimise investigator bias in these assessments. 
Imaging in TRANSEURO 
We have confirmed that imaging markers assessing the dopaminergic system correlated well with 
clinical measures such as the MDS-UPDRS motor scores, both of which tracked disease progression in 
the observational cohort. In particular, the dopamine transporter (DAT) ligand 11C-PE2I seemed to 
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have a greater predictive value and sensitivity for detecting differences in motor impairment than 
AADC imaging using 18F-DOPA. Furthermore, DAT decline seemed to be closely associated with the 
decline in motor progression over time, whereas no such relationship was found with AADC, 
suggesting that 11C-PE2I is a more objective biomarker than 18F-Dopa for investigating the effects of 
novel interventions24.  
Implications: 
Ideally one would want to be able to image everyone in the observational cohort as well as post 
grafting but this is not financially viable using PET imaging because of the costs of the scans (typically 
>£5000 per scan in the UK). Thus, we elected to scan only patients chosen for grafting along with a 
matched- control patient. We found that several measures of dopaminergic function were well suited 
for assessing dopaminergic cell transplants, including 11C-PE2I and 18F-dopa. For assessing stem cell-
derived transplants, 11C-DASB scanning (detecting serotoninergic neurons) will most likely not be 
needed given that such stem-cell products can be generated at a purity that they should not contain 
significant numbers of 5HT neurons. As for the need for fMRI studies, this is debatable for first in-
human studies, but structural MRI scans will be needed to monitor graft placement and growth as 
well as facilitate the processing and analysis of PET data post transplantation. 
The transplantation procedure 
The surgical approach for transplantation to the putamen was not seen as a critical issue given that 
we had post mortem evidence to show that the method we were adopting gave good dopamine cell 
survival and innervation across the grafted striatum (e.g. Li et al 2016). However, what did emerge as 
a major consideration was the instrument to be used for tissue delivery, given the original studies 
using cell suspension approaches employed a non-CE marked device developed in house in Lund by 
Stig Rehncrona and Janos Legradi 25. 
This instrument had been shown to deliver cells in the volume and with the accuracy needed for work 
of this type, but the absence of a CE marking meant that it could not be used in other sites. Thus, at 
the surgical centre in the UK, a new device had to be made in house based on this original instrument, 
which was not without problems, especially with respect to the ease with which the delivery device 
could be used within the outer guide sheath. This is a major issue going forward, as the routine clinical 
use of any stem cell based dopamine product for PD will require an instrument that is: (i) easy to use, 
disposable and safe; (ii) available at any site (thus CE marked for European use and FDA approved for 
use in the US) and (iii) shown not to adversely affect the viability of cells delivered to the striatum. 
Work to better define this instrument is now being undertaken. 
Implications: 
Studies using new stem cell-based dopamine therapies will need to carefully consider the delivery 
method. This is not so much referring to target sites and volume, but rather the actual instrument for 
delivery. Evidence must be provided that such an instrument is not only compatible with most 
neurosurgical centres’ practice but also with the survival of implanted cells and their capacity to 
reinnervate the denervated striatum. 
The immunosuppressive regime  
The regime for preventing rejection of the transplant is still debated as evident from previous hfVM 
trials in which treatment has varied from no immunosuppression 6, monotherapy with ciclosporin A 
(CyA) for 6 months7, or triple therapy with CyA, azathioprine and steroids for at least 12 months post-
grafting26. While no firm conclusions can be drawn, the duration and completeness of 
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immunosuppression appear to be important for optimal, long-term graft survival. However, the choice 
of which regime to adopt is not clear, especially given the problems in monitoring any rejection 
process in an intracerebrally placed graft. This coupled to the fact that it is known that; (i) human fetal 
tissue expresses low levels of MHC antigens, which are upregulated in the presence of inflammatory 
cytokines (as is found at the graft site)27; (ii) post mortem studies in grafted patients from the early 
post implantation period has revealed that there is an inflammatory infiltrate around the grafts17  and 
(iii) long term graft survival can be obtained in the absence of long term immunosuppression18,20, led 
us to adopt triple therapy of the type used previously. This was given for 12 months post grafting. In 
addition, the side effects of such a short-term immunosuppressive regime are relatively benign and 
also many of the long-term complications associated with these drugs (e.g. increased risk of solid 
tumour development with CyA) are avoided. In our trial we only had three major problems with this 
regime- one patient developed an azathioprine related colitis, which required this drug to be stopped 
Another patient developed a Kaposi sarcoma that resolved once the immunotherapy was 
discontinued, and a third showed mild signs of hepatotoxicity (increased aspartate aminotransferase  
(AST) values), that completely resolved once the azathioprine was discontinued and replaced by 
mycophenolate.   
Implications: 
For future stem cell trials, there would seem to be a need for immunosuppressive treatment to be 
continued for 12 months post grafting28,29. The optimal regime is unclear, and it also cannot be 
assumed that the graft composition and the presentation of antigens are the same in fetal as in stem 
cell-derived grafts. Some form of combination therapy, as is used in solid organ transplant 
programmes, would be best, although improved ways to measure intracerebral graft rejection are still 
urgently needed. 
Follow up, timing of primary end points and choice of comparator 
The selection of the outcome measure must include some read out around the dopamine responsive 
aspects of PD, given this is what the therapy is designed to treat. Motor measures in the “OFF” state 
are optimal for doing this although changes in ON scores and non-motor symptoms will enable 
assessment of any impact that the grafts have on non-dopaminergic aspects of disease progression 
and non-motor dopaminergic features of PD. 
As to what constitutes a major quantitative improvement is unclear, but we estimate that at least a 
30-50% improvement is needed in the MDS-UPDRS part 3 motor OFF score for this therapy to be 
viewed as competitive given its invasive nature, irrespective of looking for an effect that is greater 
than that which could be explained through any placebo effect30. While this was a reason for not using 
sham surgery in TRANSEURO, it was not the main one. The major reason for having no sham surgery 
was that this trial was not undertaken to prove that this therapy could be taken forward for clinical 
adoption as a standard of care, rather it was done to try and establish the trial framework for the next 
generation of stem cell based dopamine cells for PD. Namely it was undertaken as a further proof of 
principle study. In addition, there were also ethical concerns, given that patients in a non-
interventional sham surgery arm would be in receipt of immunosuppressive drugs and be tied into a 
trial that would prevent them from having other possible experimental treatments for at least 3 years. 
Implications; 
The first new trials with stem cell derived dopamine cell will need to address tolerability and feasibility, 
with an emphasis on safety rather than efficacy. However, we would recommend that all patients 
recruited into cell therapy trials are followed up long term, ideally indefinitely, with declarations of 
12 
 
intent for brain donation so that the long-term benefits and histological effects of these (irreversible) 
interventions can be best described. We would also recommend that a variety of end points are 
chosen that primarily focus on the dopaminergic aspects of PD, given that this is what one is treating, 
but that this also includes cognitive, motor and quality of life (QoL) measures. At some point, a double-
blind sham surgery trial should be considered, or at least if not sham surgery, some form of competing 
invasive therapeutic. Exactly when this should be done is unresolved as the FDA would recommend 
that this is part of first in human study, while we and others would advocate that this is best done 
once one has worked out how to optimally deliver the right dose of cell to the right patient.  
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Conclusion 
In this Perspective, we have summarised the rationale and structure of the clinical trial design for both 
the observational natural history and hfVM transplant arms of TRANSEURO and laid out the lessons 
we have learnt en route, and how all this can be used to optimize stem cell-based dopamine 
replacement trials entering the clinic. Importantly, the stem cell-derived neurons have the potential 
to provide solutions to two of the major problems highlighted by the TRANSEURO trial and hindering 
the further development of hfVM transplantation towards a clinically competitive treatment for PD: 
First, the stem cell-derived neurons will be available in large numbers and each transplantation session 
can, therefore, be safely planned in advance, avoiding the multiple cancellations of surgeries due to 
lack of hfVM tissue and markedly increasing the numbers of patients that can be transplanted. Second, 
compared to the grafts comprising hfVM tissue from several donors of different ages used in the 
TRANSEURO trial, the variability in outcome will conceivably be much less by the transplantation of 
well-characterized stem cell-derived cell populations. It is important to emphasize, though, that 
transplantation of stem cell-derived dopaminergic neurons to the striatum, even if leading to 
improvement of motor features, will never be a cure for PD. The degeneration of other neuronal 
systems, as is seen in all patients with PD, will continue and dopamine-resistant motor features and 
non-motor symptoms will most likely not be affected by the intrastriatal dopaminergic grafts. A stem 
cell-based dopamine replacement therapy will only be clinically competitive long-term for the PD 
patients if the motor improvements outweigh the worsening of non-motor symptoms.  
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TEXT BOX 1 
INCLUSION and EXCLUSION CRITERIA for PATIENTS IN THE OBSERVATIONAL TRANSEURO STUDY- 
IN RED ARE THOSE ADDITIONAL ONES FOR THE TRANSPLANT COHORT 
Inclusion criteria 
• PD as defined using Queen Square Brain Bank criteria 
• Disease duration ≥ 2 year and ≤ 13 years 
• Aged ≥ 30 years and ≤ 68 years at the time of grafting 
• Hoehn & Yahr stage 2 or better when “on” 
• On no therapy or only receiving standard anti PD treatment 
• No significant L-Dopa induced dyskinesia 
• Significant, ≥ 33%  response in UPDRS part III score in response to L-DOPA 
• Preserved 18F-dopa signal in ventral striatum 
 
Exclusion criteria 
• Atypical parkinsonism incl. F-DOPA PET patterns consistent with this 
• MMSE score of < 24 (<26) or evidence for dementia using DSM-IV criteria 
• Unable  to  do  normal  copying  of  interlocking  pentagons and semantic fluency score <20 
over 90 secs 
• Ongoing  major  medical  or  psychiatric  disorder  incl. depression and psychosis 
• Other concomitant treatment with neuroleptics  
• Significant drug induced dyskinesias (>2 for any body part on the AIMS scale)  
• Previous neurosurgery 
• Unable  to  be  imaged  using  MRI 
• Clinically insignificant response to Levodopa  
• Any contraindication to immunosuppression therapy. 
• Patients on anticoagulants   
• Patients who are left handed 
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TEXT BOX 2 
THE PRIMARY AND SECONDARY END POINTS OF THE TRANSEURO TRANSPLANT TRIAL 
Primary Endpoint: 
 • The change in motor MDS-UPDRS in a defined “OFF” state at 36 months post transplantation. 
“OFF” being defined as receiving no dopamine (DA) therapy for 12 hours prior to assessment or 36 
hours in the case of long acting dopamine agonists (e.g. Ropinirole slow release). 
Secondary Endpoints: 
• Change in timed motor tasks at 36 months post transplantation 
• The number of patients with dyskinesias (including L-dopa and graft induced dyskinesias) at 36 
months post transplantation. 
• L-dopa equivalence medication doses at 36 months post transplantation. 
• Number of patients on L-dopa therapy at 36 months post transplantation. 
• The amount of “OFF” time 36 months post transplantation. 
• Quality of life as assessed by PDQ-39 and calculated “overall outcome changes” 36 months post 
transplantation. 
• Changes in F-DOPA PET in transplanted patients 36 months post transplantation. 
Safety Endpoints: 
•  The number of adverse events and serious adverse events associated with the neural transplant. 
•  Laboratory Parameters – any reported changes in haematology, biochemistry or urinalysis 
measures outside the normal range. 
•  Other Safety parameters – vital signs, Physical Exam – new abnormalities will be recorded as an 
adverse event. 
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Figure 1: Overview of the TRANSEURO protocol. A: recruitment by centre, enrolment and follow-
up of patients in the observational arm including reasons for drop-out at 36 months. B: complete 
list of assessments undertaken by all patients every 12 months. At 6 months a more limited set of 
assessments were undertaken.  C: PET-imaging schedule adopted and the reasons for this.  
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FIGURE 2: 36 month data from the observational cohort. Graphs A-E show the average change 
over time across all patients and 95% CIs (shaded regions) for key clinical outcomes. The annual 
rate of change (± 95% CI) is reported above each graph. Age at entry predicts the rate of decline, 
with older patients deteriorating faster (p = 0.023). 
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TABLE 1. THE TIMETABLE OF TRANSPLANTS AND THE REASONS WHY PLANNED SURGERIES WERE 
CANCELLED. 21 transplant surgeries were completed across the 2 sites. This included 10 bilateral 
grafts that were done sequentially (i.e. at 2 different surgical operations) and one patient elected 
not to have a second transplant after their unilateral surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 2015 2016 2017  2018* Total 
Theatre slots 30 62 31 5 128 
Completed procedures 7 9 4 1 21 
Cancelled (due to) 23 53 27 4 107 
Tissue supply 15 44 24 4 87  
Tissue viability 1    1 
Scheduling issues 2 6 3  11 
Instruments 3    3 
GMP airflow 2    2 
Localisation queries  2   2 
Oncology case  1   1 
*final procedure March 2018 
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